The experimental pain medication tapentadol relieved osteoarthritis (OA) knee pain as well as the narcotic oxycodone in a recent study. The Phase II clinical trial also found that the 200-mg dose of tapentadol had fewer adverse side effects than a comparable dose of oxycodone. Drugmaker Johnson & Johnson has applied for approval of tapentadol with the U.S. Food and Drug Administration.